

CNMV  
Markets Directorate General  
C/ Edison núm. 4  
28006 Madrid

Madrid, 27 March 2025

In accordance with the provisions of article 227 of the Spanish Securities Markets and Investment Services Act (*Ley de los Mercados de Valores y de los Servicios de Inversión*), approved by Law 6/2023, of 17 March, and concordant provisions, is hereby reported the following:

#### **OTHER RELEVANT INFORMATION**

Sylentis, S.A.U., a wholly owned subsidiary of Pharma Mar, announces that the European Commission has today made public the Decision C(2024) 3629 final of May 28<sup>th</sup> 2024, by which the Company has been selected to receive a €21.1 million grant under the IPCEI (Important Projects of Common European Interest) 'Med4Cure' program. This will come from Spain's allocation of the NextGenerationEU fund from the Ministry of Science, Innovation and Universities through the CDTI (Centre for Technological Development and Innovation).

Please find attached press release that will be distributed to the media today.

## Sylentis, a PharmaMar Group company, will receive €21.1 million from the NextGenerationEU fund for research into rare diseases and the construction of a manufacturing plant

**Madrid, March 27<sup>th</sup> 2025.-** Sylentis, a PharmaMar Group (MSE:PHM) company, announces that the European Commission has today made public the Decision C(2024) 3629 final of May 28<sup>th</sup> 2024, by which the Company has been selected to receive a €21.1 million grant under the IPCEI (Important Projects of Common European Interest) 'Med4Cure' program. This will come from Spain's allocation of the NextGenerationEU fund from the Ministry of Science, Innovation and Universities through the CDTI (Centre for Technological Development and Innovation).

The entire aid will be allocated to the SYOLIGO project, which represents the first industrial deployment in Spain for the production of RNA-based drugs, as well as the development of treatments for rare diseases.

The new pharmaceutical plant located in the Madrid town of Getafe has a surface area of 6,000 m<sup>2</sup>, built under the criteria of sustainability and digitalization for maximum efficiency. The factory will have a dual purpose: to provide manufacturing services for Sylentis' needs in its research projects for rare diseases and to enter into the manufacturing of RNA-based drugs for application in various pathologies for third parties. In addition, the project will generate a positive impact on the country, as it will boost employment with the direct hiring of 86 new highly skilled positions and 350 indirect ones by 2030.

Sylentis has been the only Spanish company selected as a direct participant in the IPCEI Med4Cure program. In addition, within the SYOLIGO project, collaboration with different European partners from the pharmaceutical sector is foreseen.

*"SYOLIGO aims to establish the technological base necessary for the advancement of innovative therapies, in addition to enabling key facilities in Spain that will allow for sustainable growth and productivity. This project represents a fundamental strategic step in strengthening the European pharmaceutical industry. Sylentis and the PharmaMar Group are committed to cutting-edge research and innovation in the treatment of rare diseases," commented Andreas Segerros, CEO of Sylentis.*

RNA-based drugs are innovative, high-precision molecules that are increasingly gaining approval from health authorities worldwide. By the end of 2024, more than twenty RNA-based drugs had been approved and hundreds of therapies were in various stages of clinical development.

Med4Cure is the first IPCEI in the healthcare field and involves 14 research and development projects from 13 European companies, covering all key stages of the pharmaceutical value chain. The aim is to accelerate medical progress and foster the resilience of the EU healthcare industry by improving drug discovery, especially for unmet medical needs such as rare diseases, and developing innovative and more sustainable pharmaceutical production processes.

#### **Legal warning**

This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

#### **About PharmaMar**

PharmaMar is a biopharmaceutical company focused on the research and development of new oncology treatments, whose mission is to improve the healthcare outcomes of patients afflicted by serious diseases with our innovative medicines. The Company is inspired by the sea, driven by science, and motivated by patients with serious diseases to improve their lives by delivering novel medicines to them. PharmaMar intends to continue to be the world leader in marine medicinal discovery, development and innovation.

PharmaMar has developed and now commercializes Yondelis® in Europe by itself, as well as Zepzelca® (lurbinectedin), in the US; and Aplidin® (plitidepsin), in Australia, with different partners. In addition, it has a pipeline of drug candidates and a robust R&D oncology program. PharmaMar has other clinical-stage programs under development for several types of solid cancers: lurbinectedin, ecubectedin, PM534 and PM54.. Headquartered in Madrid (Spain), PharmaMar has subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland and The United States. PharmaMar also wholly owns Sylentis, a company dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at [www.pharmamar.com](http://www.pharmamar.com).

#### **About Sylentis**

Sylentis is a pharmaceutical company that develops innovative therapies based on gene silencing technologies or RNAi. This technology enables the design of molecules capable of selectively inhibiting the synthesis of proteins responsible for diseases. Sylentis has two molecules in the development phase that have reached clinical stages for the treatment of dry eye disease and macular degeneration, along with three other molecules in preclinical development. For more information, visit <https://sylentis.com/>

#### **About drugs based on RNA**

RNA-based drugs represent a new generation of high-precision therapies designed to modulate gene expression and treat a wide variety of diseases. They have been incorporated into healthcare systems because of their ability to precisely reduce the production of a disease-associated protein, correct a mutation, and target a variety of previously “untreatable” pathways and therapeutic targets such as extremely rare metabolic or degenerative disorders. These therapies include different technologies, such as RNA interference (RNAi), aptamers, antisense oligonucleotides (ASO) or micro-RNAs (miRNA). One of the main advantages of RNA-based drugs is their high specificity, which minimizes side effects compared to conventional treatments. In addition, many of these compounds have a prolonged effect, reducing the frequency of administration.

**Media Contact:**

Lara Vadillo – Communications Director lvadillo@pharmamar.com

Miriam Collados Gordo – Corporate Communication Manager mcollados@pharmamar.com

Phone: +34 918466000

**Capital Markets & Investor Relations:**

José Luis Moreno– VP Capital Markets & Investor Relations

Natalia Amo – Capital Markets & Investor Relations

investorrelations@pharmamar.com

Phone: +34 914444500



Or please visit our website at <https://pharmamar.com/en/>

